Oxaloacetate, a natural energy-cycle molecule sold as a heat-stabilized dietary supplement, is promoted as a way to mimic the effects of eating less. Human findings are modest and come from patients, not healthy people: fewer mood symptoms before menstruation and mixed results for fatigue after viral illness. Short-term use appears well tolerated, but long-term safety is unknown, and the case for longevity use in healthy adults remains uncertain. (Full Review)

Protocol

Low-dose longevity regimen

100 mg once or twice daily

Heat-stabilized oxaloacetate with vitamin C; no human lifespan or aging-marker trial supports this dose

High-dose fatigue regimen

1 g twice daily (2 g/day)

For 6–12 weeks, as used in ME/CFS and long COVID trials

Time of day

Morning and early afternoon, with meals

Given reports of insomnia and nausea

Time to effect

Reduced Emotional Premenstrual Symptoms

One cycle

Mood score improvements over one cycle on treatment in one small trial

Reduced Fatigue in ME/CFS and Long COVID

2–6 weeks

Fatigue changes appeared within this window in trials

Improved Cognitive Performance After Viral Illness

6 weeks

Reaction-time gains in long COVID; significant only at day 60 in ME/CFS

Benefits

Medium: Reduced emotional premenstrual symptoms

Low: Reduced fatigue in ME/CFS and long COVID; improved cognitive performance after viral illness; blood glucose regulation

Speculative: Lifespan extension; brain mitochondrial growth and neurogenesis; increased brain glucose uptake in Alzheimer's disease; acute brain injury neuroprotection; motor neuron protection; slower glioma growth; liver protection; antiviral immune defense; kidney protection in diabetes

Contraindications

Pregnancy (any trimester) and breastfeeding

Children and adolescents under 18

Active malignancy outside a supervised oncology trial

Parkinson's disease on dopaminergic therapy (any Hoehn and Yahr stage)

Inborn errors of Krebs-cycle or malate-aspartate shuttle metabolism (MDH2, GOT2 or pyruvate carboxylase deficiency)

Recurrent hypoglycemia or insulin-treated diabetes with HbA1c below 6.5%, without glucose monitoring

Key Interactions

Glucose-lowering drugs (metformin, glipizide, insulin)

Supplements with additive glucose lowering (berberine, chromium, alpha-lipoic acid)

Chemotherapy (temozolomide)

Over-the-counter stimulants (caffeine, pseudoephedrine)

Glutamate-modulating drugs (memantine, riluzole)

Over-the-counter anti-inflammatories (ibuprofen, naproxen)

Supplements sharing the redox or Krebs-cycle target (nicotinamide riboside, nicotinamide mononucleotide, alpha-ketoglutarate, malate)

Prolonged fasting or ketogenic diet (very-low-carbohydrate, high-fat eating)

Risk & Side Effects

High: Gastrointestinal upset

Low: Insomnia and stimulant-like jitteriness; headache; worsening of Parkinson's symptoms

Speculative: Low blood sugar; impaired muscle endurance; mitochondrial membrane damage; theoretical support of tumor growth

Monitoring

Marker	Target	Why
Fasting glucose	75–90 mg/dL	Detect glucose lowering
HbA1c	4.8–5.4%	Longer-term glucose trend
Fasting insulin	2–6 µIU/mL	Insulin sensitivity
ALT	10–25 U/L	Liver safety
AST	10–25 U/L	Liver safety; oxaloacetate-handling enzyme
eGFR	Above 90 mL/min/1.73 m²	Kidney clearance
Plasma oxaloacetate	No established target; track change from own baseline	Absorption check
Chalder Fatigue Questionnaire	No established target; track at least 25% reduction from own baseline	Fatigue response

Cadence: Baseline before starting; fasting glucose weekly for the first 4 weeks when combined with glucose-lowering drugs; full panel and fatigue score repeated at 6–12 weeks; then every 6–12 months with continued use

Qualitative Assessment

Daytime energy and post-exertional recovery
Mental clarity and concentration
Sleep onset and continuity
Digestive comfort after doses
Mood and premenstrual symptom severity, where relevant
For Parkinson's disease, motor steadiness and tremor

Oxaloacetate for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment